

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/267,963	03/12/1999	KOHEI MIYAZONO	LUD-5539.1-C	7799
24972 7.	590 05/21/2002	1	·	
FULBRIGHT & JAWORSKI, LLP 666 FIFTH AVE NEW YORK, NY 10103-3198			EXAMINER	
			ROMEO, DAVID S	
		****	ART UNIT	PAPER NUMBER
		Į.	1647	
		I	DATE MAILED: 05/21/2002	23

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Application No. Applicant(s)			
	09/267,963	MIYAZONO ET AL.			
Office Action Summary	Examiner	Art Unit	11.00		
	David S Romeo	1647			
The MAILING DATE of this communication appeared for Reply	opears on the cover sheet w	vith the correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPITHE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a re  - If NO period for reply is specified above, the maximum statutory perior  - Failure to reply within the set or extended period for reply will, by statu  - Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a ply within the statutory minimum of the distribution of the distrib	reply be timely filed irty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
Status  1) Pagangaiya ta communication(s) filed on 07	Moroh 2002				
1) Responsive to communication(s) filed on <u>07</u>					
,	his action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims					
4)⊠ Claim(s) <u>29-53</u> is/are pending in the applicat	ion				
4a) Of the above claim(s) 29-42,50,51 and 53		esideration			
5) Claim(s) is/are allowed.	iorare withdrawn from con	isiaci allori.			
6)⊠ Claim(s) <u>43-49, 52</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 29-53 are subject to restriction and/o	or election requirement				
Application Papers	or oloculor roquiromonic.				
9) The specification is objected to by the Examin	er.				
10)☐ The drawing(s) filed on is/are: a)☐ acco	epted or b)  objected to by	the Examiner.			
Applicant may not request that any objection to t	he drawing(s) be held in abey	ance. See 37 CFR 1.85(a).			
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.					
If approved, corrected drawings are required in re	eply to this Office action.				
12)☐ The oath or declaration is objected to by the E	xaminer.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign	gn priority under 35 U.S.C.	§ 119(a)-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documer	nts have been received.				
2. Certified copies of the priority documer	nts have been received in a	Application No			
3. Copies of the certified copies of the pricapplication from the International B	ureau (PCT Rule 17.2(a)).	-			
* See the attached detailed Office action for a lis	·		_ \		
14) Acknowledgment is made of a claim for domes	•		n).		
<ul> <li>a)  The translation of the foreign language pi</li> <li>15) Acknowledgment is made of a claim for domes</li> </ul>	• •				
Attachment(s)	_				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)			

Application/Control Number: 09/267,963

Art Unit: 1647

5

10

## **DETAILED ACTION**

Claims 29-53 are pending.

Applicant's election with traverse of group II, claims 43-52 to the extent that they are drawn to a method for determining if a substance inhibits TGF-β/Alk-1 induced Smad1 phosporylation, in Paper No. 20 is acknowledged. The traversal is on the ground(s) that all the groups relate to the interaction of TGF-β and ALK-1 and all are classified the same. This is not found persuasive because, considering the independent claims in each group, the methods are independent and distinct, wherein each performs different functions, using different starting materials, and can be practiced independently. Furthermore, the arts of Smad1 and Smad5 phosporylation are not coextensive and require separate searches.

The requirement is still deemed proper and is therefore made FINAL.

Claims 29-42, 53 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 22. Since Applicants elected group II, claims 43-52 to the extent that they are drawn to a method for determining if a substance inhibits TGF-β/Alk-1 induced Smad1 phosporylation, and since claims 47, 50, 51 are directed to Smad5 phosporylation, and since Applicants could have but did not elect group III directed to Smad5 phosporylation, claims 47, 50, 51 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), to the extent that they are drawn to a nonelected invention, there being no allowable generic or linking claim.

Application/Control Number: 09/267,963

Art Unit: 1647

5

10

15

20

Page 3

Claims 43-49, 52 are being examined to the extent that they are drawn to a method for determining if a substance inhibits TGF-β/Alk-1 induced Smad1 phosporylation.

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 43-49, 52 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification teaches that ALK-1 binds TGF-β1 and Activin A in the presence of their respective type II receptors, but the functional consequences of the binding of the ligands remains to be elucidated (page 34, full paragraph 2). ALK-1 is a receptor for TGF-β (page 35, lines 19-20). Smad1 was phosphorylated following interaction with a constitutively active ALK-1 (page 36, lines 18-22). Leading the specification to assert that TGF-β binds to ALK-1 leading to phosporylation of Smad1 (page 37, lines 26-27). However, there are no working examples demonstrating that TGF-β binds to ALK-1 leading to phosporylation of Smad1. Although, the specification discloses that TGF-β binds Alk1, there is no indication that this binding effects or activates the receptor in any way. Binding does not equal activating. It would be reasonable to conclude that it would require undue experimentation to use the invention.

Application/Control Number: 09/267,963

Art Unit: 1647

Claim 52 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification teaches that Smad1 was phosphorylated following interaction with a constitutively active ALK-1 (page 36, lines 18-22). In other words, in the presence of constitutively active ALK-1 phosphorylates Smad1 regardless of the presence or absence of TGF-β. In the presence of constitutively active ALK-1 either there is no TGF-β/Alk-1 induced Smad1 phosporylation or the skilled artisan would be unable to distinguish TGF-β/Alk-1 induced Smad1 phosporylation from constitutively active ALK-1 induced phosporylation. Thus, there would be no way to determine if a substance inhibits TGF-β/Alk-1 induced Smad1 phosporylation in the presence of constitutively active Alk-1. There are no working examples of such a determination. It would be reasonable to conclude that it would require undue

Page 4

15

10

5

## Conclusion

No claims are allowed.

experimentation to use the invention.

ANY INQUIRY CONCERNING THIS COMMUNICATION OR EARLIER COMMUNICATIONS FROM THE EXAMINER SHOULD BE DIRECTED TO DAVID S. ROMEO WHOSE TELEPHONE NUMBER IS (703) 305-4050. THE EXAMINER CAN NORMALLY BE REACHED ON MONDAY THROUGH FRIDAY FROM 7:30 A.M. TO 4:00 P.M.

IF ATTEMPTS TO REACH THE EXAMINER BY TELEPHONE ARE UNSUCCESSFUL, THE EXAMINER'S SUPERVISOR, GARY KUNZ, CAN BE REACHED ON (703) 308-4623.

IF SUBMITTING OFFICIAL CORRESPONDENCE BY FAX, APPLICANTS ARE ENCOURAGED TO SUBMIT OFFICIAL CORRESPONDENCE TO THE FOLLOWING TC 1600 BEFORE AND AFTER FINAL RIGHTFAX NUMBERS:

BEFORE FINAL (703) 872-9306 AFTER FINAL (703) 872-9307

IN ADDITION TO THE OFFICIAL RIGHTFAX NUMBERS ABOVE, THE TC 1600 FAX CENTER HAS THE FOLLOWING OFFICIAL FAX NUMBERS: (703) 305-3592, (703) 308-4242 AND (703) 305-3014.

Application/Control Number: 09/267,963 Page 5

Art Unit: 1647

CUSTOMERS ARE ALSO ADVISED TO USE CERTIFICATE OF FACSIMILE PROCEDURES WHEN SUBMITTING A REPLY TO A NON-FINAL OR FINAL OFFICE ACTION BY FACSIMILE (SEE 37 CFR 1.6 AND 1.8).

FAXED DRAFT OR INFORMAL COMMUNICATIONS SHOULD BE DIRECTED TO THE EXAMINER AT (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

10

5

Dome Rome

DAVID ROMEO PRIMARY EXAMINER ART UNIT 1647

DSR

15 MAY 20, 2002